Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
41.10
+1.51 (+3.81%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
716,038
Open
40.00
Bid (Size)
38.33 (1)
Ask (Size)
42.00 (3)
Prev. Close
39.59
Today's Range
39.99 - 41.32
52wk Range
18.63 - 41.43
Shares Outstanding
67,473,870
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
November 22, 2024
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?
Via
Chartmill
Smaller Cap Biotechs Are In Season: How Are We Doing?
November 07, 2024
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via
Talk Markets
Performance
YTD
+50.00%
+50.00%
1 Month
+20.46%
+20.46%
3 Month
+27.13%
+27.13%
6 Month
+91.61%
+91.61%
1 Year
+55.86%
+55.86%
More News
Read More
Veracyte Announces Third Quarter 2024 Financial Results
November 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
October 30, 2024
From
Veracyte, Inc.
Via
Business Wire
Breaking Down Veracyte: 4 Analysts Share Their Views
October 10, 2024
Via
Benzinga
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
October 16, 2024
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
October 02, 2024
From
Veracyte, Inc.
Via
Business Wire
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
September 16, 2024
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
September 15, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
September 04, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
August 26, 2024
From
Veracyte, Inc.
Via
Business Wire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Via
Investor's Business Daily
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
Via
Benzinga
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
August 07, 2024
Via
Benzinga
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
August 07, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 07, 2024
Via
InvestorPlace
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Veracyte Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Veracyte, Inc.
Via
Business Wire
The 3 Best Personalized Nutrition Stocks to Buy Now
July 24, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
July 17, 2024
From
Veracyte, Inc.
Via
Business Wire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via
Talk Markets
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
Via
Benzinga
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
June 03, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.